Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

5.46

Margin Of Safety %

Put/Call OI Ratio

0.44

EPS Next Q Diff

-0.31

EPS Last/This Y

-3.99

EPS This/Next Y

-0.51

Price

5.06

Target Price

17.1

Analyst Recom

1.08

Performance Q

-35.9

Relative Volume

0.4

Beta

0.91

Ticker: VYGR




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19VYGR5.70.633.004904
2024-12-20VYGR5.760.660.005020
2024-12-23VYGR5.730.360.103561
2024-12-24VYGR5.780.360.003570
2024-12-26VYGR5.910.367.003582
2024-12-27VYGR5.740.370.003604
2024-12-30VYGR5.590.370.003621
2024-12-31VYGR5.680.370.003629
2025-01-02VYGR5.970.350.023678
2025-01-03VYGR6.050.330.013851
2025-01-06VYGR6.010.310.044093
2025-01-07VYGR5.930.310.004069
2025-01-08VYGR5.750.310.004072
2025-01-09VYGR5.730.310.004072
2025-01-10VYGR5.440.310.354073
2025-01-13VYGR5.280.332.104209
2025-01-14VYGR5.050.382.174474
2025-01-15VYGR5.180.430.964688
2025-01-16VYGR5.050.430.924700
2025-01-17VYGR5.060.440.114834
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19VYGR5.71-127.2- -0.91
2024-12-20VYGR5.76-127.2- -0.91
2024-12-23VYGR5.73-127.2- -0.91
2024-12-24VYGR5.78-127.2- -0.91
2024-12-26VYGR5.91-127.2- -0.91
2024-12-27VYGR5.74-127.2- -0.91
2024-12-30VYGR5.59-127.2- -0.91
2024-12-31VYGR5.68-127.2- -0.91
2025-01-02VYGR5.97-127.2- -0.91
2025-01-03VYGR6.04-127.2- -0.91
2025-01-06VYGR6.02-127.2- -0.91
2025-01-07VYGR5.93-127.2- -0.91
2025-01-08VYGR5.73-127.2- -0.91
2025-01-09VYGR5.73-127.2- -0.91
2025-01-10VYGR5.44-127.2- -0.91
2025-01-13VYGR5.29-127.2- -0.91
2025-01-14VYGR5.05-127.2- -0.91
2025-01-15VYGR5.19-127.2- -0.91
2025-01-16VYGR5.05-127.2- -0.91
2025-01-17VYGR5.06-127.2- -0.91
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19VYGR-0.06-4.795.66
2024-12-20VYGR-0.06-4.795.66
2024-12-23VYGR-0.06-4.735.66
2024-12-24VYGR-0.06-4.735.66
2024-12-26VYGR-0.13-4.735.60
2024-12-27VYGR-0.13-4.735.60
2024-12-30VYGR-0.14-4.595.60
2024-12-31VYGR-0.14-4.595.61
2025-01-02VYGR-0.13-4.595.61
2025-01-03VYGR-0.13-4.595.61
2025-01-06VYGR-0.13-4.735.61
2025-01-07VYGR-0.13-4.735.61
2025-01-08VYGR-0.13-4.735.61
2025-01-09VYGR-0.13-4.735.61
2025-01-10VYGR-0.13-4.735.61
2025-01-13VYGR-0.13-4.725.46
2025-01-14VYGR-0.13-4.725.46
2025-01-15VYGR-0.18-4.725.46
2025-01-16VYGR-0.18-4.725.46
2025-01-17VYGR-0.18-4.725.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.34

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

-0.18

Institutional Transactions

-4.72

Beta

0.91

Average Sales Estimate Current Quarter

17

Average Sales Estimate Next Quarter

11

Fair Value

Quality Score

51

Growth Score

39

Sentiment Score

3

Actual DrawDown %

65.8

Max Drawdown 5-Year %

-83.2

Target Price

17.1

P/E

7.03

Forward P/E

PEG

P/S

1.69

P/B

0.84

P/Free Cash Flow

EPS

0.72

Average EPS Est. Cur. Y​

-0.91

EPS Next Y. (Est.)

-1.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

15.8

Relative Volume

0.4

Return on Equity vs Sector %

-11.2

Return on Equity vs Industry %

1.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.33

EBIT Estimation

Voyager Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 162
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
stock quote shares  VYGR – Voyager Therapeutics, Inc. Stock Price stock today
news today  VYGR – Voyager Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  VYGR – Voyager Therapeutics, Inc. yahoo finance google finance
stock history  VYGR – Voyager Therapeutics, Inc. invest stock market
stock prices VYGR premarket after hours
ticker VYGR fair value insiders trading